Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) Stock Competitors & Peer Comparison
See DMII's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Financial - Conglomerates Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for DMII and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| DMII | $10.14 | +0.00% | 645.9M | 72.43 | $0.14 | N/A |
| EP-PC | $50.25 | -0.15% | 111.7B | 28.30 | $1.78 | +4.73% |
| FRHC | $170.66 | +4.26% | 10.5B | 67.99 | $2.51 | N/A |
| BIPH | $15.92 | -0.25% | 5.8B | N/A | N/A | +7.83% |
| MSDL | $15.36 | -0.13% | 1.3B | 7.84 | $1.96 | +12.36% |
| RILYK | $25.23 | +0.16% | 787.6M | N/A | N/A | N/A |
| RILYM | $25.11 | +0.00% | 753M | N/A | N/A | N/A |
| CCXIU | $15.02 | -6.13% | 611.3M | N/A | N/A | N/A |
| RILYO | $25.13 | -0.02% | 573.5M | N/A | N/A | N/A |
| TMS | $7.34 | +0.96% | 528.4M | N/A | N/A | N/A |
Stock Comparison
El Paso Energy Capital Trust I PFD CV TR SECS (NYSE: EP-PC)
DMII vs EP-PC Comparison August 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 645.9M. In comparison, EP-PC has a market cap of 111.7B. Regarding current trading prices, DMII is priced at $10.14 on the NASDAQ, while EP-PC trades at $50.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.43, whereas EP-PC's P/E ratio is 28.30. In terms of profitability, DMII's ROE is +0.03%, compared to EP-PC's ROE of +0.11%. Regarding short-term risk, DMII is less volatile compared to EP-PC. This indicates lower risk in terms of short-term price fluctuations for DMII.Check EP-PC's competition here
Freedom Holding Corp. (NASDAQ: FRHC)
DMII vs FRHC Comparison August 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 645.9M. In comparison, FRHC has a market cap of 10.5B. Regarding current trading prices, DMII is priced at $10.14 on the NASDAQ, while FRHC trades at $170.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.43, whereas FRHC's P/E ratio is 67.99. In terms of profitability, DMII's ROE is +0.03%, compared to FRHC's ROE of +0.11%. Regarding short-term risk, DMII is less volatile compared to FRHC. This indicates lower risk in terms of short-term price fluctuations for DMII.Check FRHC's competition here
Brookfield Infrastructure Finance ULC 5 % Notes 2021-24.05.81 Global (NYSE: BIPH)
DMII vs BIPH Comparison August 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 645.9M. In comparison, BIPH has a market cap of 5.8B. Regarding current trading prices, DMII is priced at $10.14 on the NASDAQ, while BIPH trades at $15.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.43, whereas BIPH's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to BIPH's ROE of +0.06%. Regarding short-term risk, DMII is less volatile compared to BIPH. This indicates lower risk in terms of short-term price fluctuations for DMII.Check BIPH's competition here
Morgan Stanley Direct Lending Fund (NYSE: MSDL)
DMII vs MSDL Comparison August 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 645.9M. In comparison, MSDL has a market cap of 1.3B. Regarding current trading prices, DMII is priced at $10.14 on the NASDAQ, while MSDL trades at $15.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.43, whereas MSDL's P/E ratio is 7.84. In terms of profitability, DMII's ROE is +0.03%, compared to MSDL's ROE of +0.03%. Regarding short-term risk, DMII is less volatile compared to MSDL. This indicates lower risk in terms of short-term price fluctuations for DMII.Check MSDL's competition here
B. Riley Financial, Inc. 5.50% Senior Notes Due 2026 (NASDAQ: RILYK)
DMII vs RILYK Comparison August 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 645.9M. In comparison, RILYK has a market cap of 787.6M. Regarding current trading prices, DMII is priced at $10.14 on the NASDAQ, while RILYK trades at $25.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.43, whereas RILYK's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to RILYK's ROE of -7.75%. Regarding short-term risk, DMII is less volatile compared to RILYK. This indicates lower risk in terms of short-term price fluctuations for DMII.Check RILYK's competition here
B. Riley Financial, Inc. - 6.37 (NASDAQ: RILYM)
DMII vs RILYM Comparison August 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 645.9M. In comparison, RILYM has a market cap of 753M. Regarding current trading prices, DMII is priced at $10.14 on the NASDAQ, while RILYM trades at $25.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.43, whereas RILYM's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to RILYM's ROE of -7.75%. Regarding short-term risk, DMII is less volatile compared to RILYM. This indicates lower risk in terms of short-term price fluctuations for DMII.Check RILYM's competition here
Churchill Capital Corp XI Units (NASDAQ: CCXIU)
DMII vs CCXIU Comparison August 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 645.9M. In comparison, CCXIU has a market cap of 611.3M. Regarding current trading prices, DMII is priced at $10.14 on the NASDAQ, while CCXIU trades at $15.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.43, whereas CCXIU's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to CCXIU's ROE of -0.59%. Regarding short-term risk, DMII is less volatile compared to CCXIU. This indicates lower risk in terms of short-term price fluctuations for DMII.Check CCXIU's competition here
B. Riley Financial, Inc. - 6.75 (NASDAQ: RILYO)
DMII vs RILYO Comparison August 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 645.9M. In comparison, RILYO has a market cap of 573.5M. Regarding current trading prices, DMII is priced at $10.14 on the NASDAQ, while RILYO trades at $25.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.43, whereas RILYO's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to RILYO's ROE of -7.75%. Regarding short-term risk, DMII is less volatile compared to RILYO. This indicates lower risk in terms of short-term price fluctuations for DMII.Check RILYO's competition here
Teamshares Inc. (NASDAQ: TMS)
DMII vs TMS Comparison August 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 645.9M. In comparison, TMS has a market cap of 528.4M. Regarding current trading prices, DMII is priced at $10.14 on the NASDAQ, while TMS trades at $7.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.43, whereas TMS's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to TMS's ROE of N/A. Regarding short-term risk, DMII is less volatile compared to TMS. This indicates lower risk in terms of short-term price fluctuations for DMII.Check TMS's competition here
Voyager Acquisition Corp. (NASDAQ: VACHU)
DMII vs VACHU Comparison August 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 645.9M. In comparison, VACHU has a market cap of 475.5M. Regarding current trading prices, DMII is priced at $10.14 on the NASDAQ, while VACHU trades at $14.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.43, whereas VACHU's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to VACHU's ROE of +0.04%. Regarding short-term risk, DMII is less volatile compared to VACHU. This indicates lower risk in terms of short-term price fluctuations for DMII.Check VACHU's competition here
Legato Merger Corp. III (AMEX: LEGT-UN)
DMII vs LEGT-UN Comparison August 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 645.9M. In comparison, LEGT-UN has a market cap of 467.4M. Regarding current trading prices, DMII is priced at $10.14 on the NASDAQ, while LEGT-UN trades at $18.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.43, whereas LEGT-UN's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to LEGT-UN's ROE of +0.04%. Regarding short-term risk, DMII is less volatile compared to LEGT-UN. This indicates lower risk in terms of short-term price fluctuations for DMII.Check LEGT-UN's competition here
Gores Holdings XI, Inc. Class A Ordinary Shares (NASDAQ: GHXI)
DMII vs GHXI Comparison August 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 645.9M. In comparison, GHXI has a market cap of 362.5M. Regarding current trading prices, DMII is priced at $10.14 on the NASDAQ, while GHXI trades at $10.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.43, whereas GHXI's P/E ratio is -7723.08. In terms of profitability, DMII's ROE is +0.03%, compared to GHXI's ROE of N/A. Regarding short-term risk, DMII is less volatile compared to GHXI. This indicates lower risk in terms of short-term price fluctuations for DMII.Check GHXI's competition here
Cantor Equity Partners II, Inc. (NASDAQ: CEPT)
DMII vs CEPT Comparison August 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 645.9M. In comparison, CEPT has a market cap of 360.2M. Regarding current trading prices, DMII is priced at $10.14 on the NASDAQ, while CEPT trades at $11.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.43, whereas CEPT's P/E ratio is -107.09. In terms of profitability, DMII's ROE is +0.03%, compared to CEPT's ROE of +0.01%. Regarding short-term risk, DMII is less volatile compared to CEPT. This indicates lower risk in terms of short-term price fluctuations for DMII.Check CEPT's competition here
RRE Ventures Acquisition Corp. (NASDAQ: RREV)
DMII vs RREV Comparison August 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 645.9M. In comparison, RREV has a market cap of 331.3M. Regarding current trading prices, DMII is priced at $10.14 on the NASDAQ, while RREV trades at $9.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.43, whereas RREV's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to RREV's ROE of -31.07%. Regarding short-term risk, DMII is less volatile compared to RREV. This indicates lower risk in terms of short-term price fluctuations for DMII.Check RREV's competition here
Safeguard Acquisition Corp. (NYSE: SAC)
DMII vs SAC Comparison August 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 645.9M. In comparison, SAC has a market cap of 317.3M. Regarding current trading prices, DMII is priced at $10.14 on the NASDAQ, while SAC trades at $10.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.43, whereas SAC's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to SAC's ROE of +0.00%. Regarding short-term risk, DMII is less volatile compared to SAC. This indicates lower risk in terms of short-term price fluctuations for DMII.Check SAC's competition here
Osprey Acquisition Corp. III (NASDAQ: OSPRU)
DMII vs OSPRU Comparison August 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 645.9M. In comparison, OSPRU has a market cap of 310.7M. Regarding current trading prices, DMII is priced at $10.14 on the NASDAQ, while OSPRU trades at $10.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.43, whereas OSPRU's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to OSPRU's ROE of N/A. Regarding short-term risk, DMII is less volatile compared to OSPRU. This indicates lower risk in terms of short-term price fluctuations for DMII.Check OSPRU's competition here
Velos Acquisition I Corp. (NASDAQ: VLOS)
DMII vs VLOS Comparison August 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 645.9M. In comparison, VLOS has a market cap of 310.5M. Regarding current trading prices, DMII is priced at $10.14 on the NASDAQ, while VLOS trades at $10.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.43, whereas VLOS's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to VLOS's ROE of N/A. Regarding short-term risk, DMII is similarly volatile compared to VLOS. This indicates similar risk in terms of short-term price fluctuations for DMII.Check VLOS's competition here
B. Riley Financial, Inc. 5.00% Senior Notes due 2026 (NASDAQ: RILYG)
DMII vs RILYG Comparison August 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 645.9M. In comparison, RILYG has a market cap of 308.5M. Regarding current trading prices, DMII is priced at $10.14 on the NASDAQ, while RILYG trades at $24.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.43, whereas RILYG's P/E ratio is -3.77. In terms of profitability, DMII's ROE is +0.03%, compared to RILYG's ROE of -7.75%. Regarding short-term risk, DMII is less volatile compared to RILYG. This indicates lower risk in terms of short-term price fluctuations for DMII.Check RILYG's competition here
B. Riley Financial, Inc. 6.00% Senior Notes Due 2028 (NASDAQ: RILYT)
DMII vs RILYT Comparison August 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 645.9M. In comparison, RILYT has a market cap of 308.5M. Regarding current trading prices, DMII is priced at $10.14 on the NASDAQ, while RILYT trades at $21.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.43, whereas RILYT's P/E ratio is 2.96. In terms of profitability, DMII's ROE is +0.03%, compared to RILYT's ROE of -7.75%. Regarding short-term risk, DMII is less volatile compared to RILYT. This indicates lower risk in terms of short-term price fluctuations for DMII.Check RILYT's competition here
Velos Acquisition I Corp. (NASDAQ: VLOSU)
DMII vs VLOSU Comparison August 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 645.9M. In comparison, VLOSU has a market cap of 307.9M. Regarding current trading prices, DMII is priced at $10.14 on the NASDAQ, while VLOSU trades at $10.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.43, whereas VLOSU's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to VLOSU's ROE of N/A. Regarding short-term risk, DMII is similarly volatile compared to VLOSU. This indicates similar risk in terms of short-term price fluctuations for DMII.Check VLOSU's competition here
BRC Group Holdings Inc. 5.25% Sr. Notes due 2028 (NASDAQ: RILYZ)
DMII vs RILYZ Comparison August 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 645.9M. In comparison, RILYZ has a market cap of 299.5M. Regarding current trading prices, DMII is priced at $10.14 on the NASDAQ, while RILYZ trades at $19.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.43, whereas RILYZ's P/E ratio is 4.01. In terms of profitability, DMII's ROE is +0.03%, compared to RILYZ's ROE of -7.75%. Regarding short-term risk, DMII is less volatile compared to RILYZ. This indicates lower risk in terms of short-term price fluctuations for DMII.Check RILYZ's competition here
BRC Group Holdings, Inc. - Depositary Shares, each representing a 1/1000th fractional interest in a share of Series B Cumulative Perpetual Preferred Stock (NASDAQ: RILYL)
DMII vs RILYL Comparison August 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 645.9M. In comparison, RILYL has a market cap of 295.2M. Regarding current trading prices, DMII is priced at $10.14 on the NASDAQ, while RILYL trades at $13.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.43, whereas RILYL's P/E ratio is 0.92. In terms of profitability, DMII's ROE is +0.03%, compared to RILYL's ROE of -7.75%. Regarding short-term risk, DMII is less volatile compared to RILYL. This indicates lower risk in terms of short-term price fluctuations for DMII.Check RILYL's competition here
BRC Group Holdings, Inc. 6.50% Senior Notes Due 2026 (NASDAQ: RILYN)
DMII vs RILYN Comparison August 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 645.9M. In comparison, RILYN has a market cap of 293.3M. Regarding current trading prices, DMII is priced at $10.14 on the NASDAQ, while RILYN trades at $25.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.43, whereas RILYN's P/E ratio is 1.39. In terms of profitability, DMII's ROE is +0.03%, compared to RILYN's ROE of -7.75%. Regarding short-term risk, DMII is less volatile compared to RILYN. This indicates lower risk in terms of short-term price fluctuations for DMII.Check RILYN's competition here
BRC Group Holdings, Inc. (NASDAQ: RILY)
DMII vs RILY Comparison August 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 645.9M. In comparison, RILY has a market cap of 286.2M. Regarding current trading prices, DMII is priced at $10.14 on the NASDAQ, while RILY trades at $7.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.43, whereas RILY's P/E ratio is 0.56. In terms of profitability, DMII's ROE is +0.03%, compared to RILY's ROE of -7.75%. Regarding short-term risk, DMII is less volatile compared to RILY. This indicates lower risk in terms of short-term price fluctuations for DMII.Check RILY's competition here
BRC Group Holdings, Inc. - Depositary Shares, each representing a 1/1000th fractional interest in a share of Series A Cumulative Perpetual Preferred Stock (NASDAQ: RILYP)
DMII vs RILYP Comparison August 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 645.9M. In comparison, RILYP has a market cap of 284.9M. Regarding current trading prices, DMII is priced at $10.14 on the NASDAQ, while RILYP trades at $12.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.43, whereas RILYP's P/E ratio is 0.88. In terms of profitability, DMII's ROE is +0.03%, compared to RILYP's ROE of -7.75%. Regarding short-term risk, DMII is less volatile compared to RILYP. This indicates lower risk in terms of short-term price fluctuations for DMII.Check RILYP's competition here
NewHold Investment Corp IV Class A Ordinary Shares (NASDAQ: NHIV)
DMII vs NHIV Comparison August 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 645.9M. In comparison, NHIV has a market cap of 278.6M. Regarding current trading prices, DMII is priced at $10.14 on the NASDAQ, while NHIV trades at $10.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.43, whereas NHIV's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to NHIV's ROE of N/A. Regarding short-term risk, DMII is similarly volatile compared to NHIV. This indicates similar risk in terms of short-term price fluctuations for DMII.Check NHIV's competition here
Mountain Lake Acquisition Corp. II Class A Ordinary Shares (NASDAQ: MLAA)
DMII vs MLAA Comparison August 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 645.9M. In comparison, MLAA has a market cap of 261.3M. Regarding current trading prices, DMII is priced at $10.14 on the NASDAQ, while MLAA trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.43, whereas MLAA's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to MLAA's ROE of N/A. Regarding short-term risk, DMII is less volatile compared to MLAA. This indicates lower risk in terms of short-term price fluctuations for DMII.Check MLAA's competition here
Art Technology Acquisition Corp. (NASDAQ: ARTC)
DMII vs ARTC Comparison August 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 645.9M. In comparison, ARTC has a market cap of 260.5M. Regarding current trading prices, DMII is priced at $10.14 on the NASDAQ, while ARTC trades at $9.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.43, whereas ARTC's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to ARTC's ROE of N/A. Regarding short-term risk, DMII is less volatile compared to ARTC. This indicates lower risk in terms of short-term price fluctuations for DMII.Check ARTC's competition here
Roman DBDR Acquisition Corp. II (NASDAQ: DRDBU)
DMII vs DRDBU Comparison August 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 645.9M. In comparison, DRDBU has a market cap of 259.7M. Regarding current trading prices, DMII is priced at $10.14 on the NASDAQ, while DRDBU trades at $11.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.43, whereas DRDBU's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to DRDBU's ROE of +0.02%. Regarding short-term risk, DMII is less volatile compared to DRDBU. This indicates lower risk in terms of short-term price fluctuations for DMII.Check DRDBU's competition here
Keystone Acquisition Corp. Unit (NASDAQ: KEYYU)
DMII vs KEYYU Comparison August 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 645.9M. In comparison, KEYYU has a market cap of 253.5M. Regarding current trading prices, DMII is priced at $10.14 on the NASDAQ, while KEYYU trades at $10.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.43, whereas KEYYU's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to KEYYU's ROE of N/A. Regarding short-term risk, DMII is similarly volatile compared to KEYYU. This indicates similar risk in terms of short-term price fluctuations for DMII.Check KEYYU's competition here
OneIM Acquisition Corp. Warrant (NASDAQ: OIMAW)
DMII vs OIMAW Comparison August 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 645.9M. In comparison, OIMAW has a market cap of 250M. Regarding current trading prices, DMII is priced at $10.14 on the NASDAQ, while OIMAW trades at $0.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.43, whereas OIMAW's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to OIMAW's ROE of N/A. Regarding short-term risk, DMII is less volatile compared to OIMAW. This indicates lower risk in terms of short-term price fluctuations for DMII.Check OIMAW's competition here
Dynamix Corporation Warrant - on Dynamix (NASDAQ: DYNCW)
DMII vs DYNCW Comparison August 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 645.9M. In comparison, DYNCW has a market cap of 248.5M. Regarding current trading prices, DMII is priced at $10.14 on the NASDAQ, while DYNCW trades at $0.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.43, whereas DYNCW's P/E ratio is -0.22. In terms of profitability, DMII's ROE is +0.03%, compared to DYNCW's ROE of N/A. Regarding short-term risk, DMII is less volatile compared to DYNCW. This indicates lower risk in terms of short-term price fluctuations for DMII.Check DYNCW's competition here
Legato Merger Corp. III (AMEX: LEGT)
DMII vs LEGT Comparison August 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 645.9M. In comparison, LEGT has a market cap of 247.2M. Regarding current trading prices, DMII is priced at $10.14 on the NASDAQ, while LEGT trades at $9.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.43, whereas LEGT's P/E ratio is 72.34. In terms of profitability, DMII's ROE is +0.03%, compared to LEGT's ROE of +0.04%. Regarding short-term risk, DMII is less volatile compared to LEGT. This indicates lower risk in terms of short-term price fluctuations for DMII.Check LEGT's competition here
Roman DBDR Acquisition Corp. II (NASDAQ: DRDB)
DMII vs DRDB Comparison August 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 645.9M. In comparison, DRDB has a market cap of 245.2M. Regarding current trading prices, DMII is priced at $10.14 on the NASDAQ, while DRDB trades at $10.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.43, whereas DRDB's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to DRDB's ROE of +0.02%. Regarding short-term risk, DMII is less volatile compared to DRDB. This indicates lower risk in terms of short-term price fluctuations for DMII.Check DRDB's competition here
Illumination Acquisition Corp I (NASDAQ: ILLUU)
DMII vs ILLUU Comparison August 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 645.9M. In comparison, ILLUU has a market cap of 239.5M. Regarding current trading prices, DMII is priced at $10.14 on the NASDAQ, while ILLUU trades at $10.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.43, whereas ILLUU's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to ILLUU's ROE of +0.00%. Regarding short-term risk, DMII is similarly volatile compared to ILLUU. This indicates similar risk in terms of short-term price fluctuations for DMII.Check ILLUU's competition here
Space Asset Acquisition Corp. Class A Ordinary Shares (NASDAQ: SAAQ)
DMII vs SAAQ Comparison August 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 645.9M. In comparison, SAAQ has a market cap of 239.3M. Regarding current trading prices, DMII is priced at $10.14 on the NASDAQ, while SAAQ trades at $10.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.43, whereas SAAQ's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to SAAQ's ROE of +0.00%. Regarding short-term risk, DMII is similarly volatile compared to SAAQ. This indicates similar risk in terms of short-term price fluctuations for DMII.Check SAAQ's competition here
Quantum Leap Acquisition Corp (NYSE: QLEP)
DMII vs QLEP Comparison August 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 645.9M. In comparison, QLEP has a market cap of 236.5M. Regarding current trading prices, DMII is priced at $10.14 on the NASDAQ, while QLEP trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.43, whereas QLEP's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to QLEP's ROE of N/A. Regarding short-term risk, DMII is similarly volatile compared to QLEP. This indicates similar risk in terms of short-term price fluctuations for DMII.Check QLEP's competition here
Illumination Acquisition Corp I Class A Ordinary Shares (NASDAQ: ILLU)
DMII vs ILLU Comparison August 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 645.9M. In comparison, ILLU has a market cap of 235.5M. Regarding current trading prices, DMII is priced at $10.14 on the NASDAQ, while ILLU trades at $9.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.43, whereas ILLU's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to ILLU's ROE of +0.00%. Regarding short-term risk, DMII is similarly volatile compared to ILLU. This indicates similar risk in terms of short-term price fluctuations for DMII.Check ILLU's competition here
Bluerock Acquisition Corp. Class A Ordinary Shares (NASDAQ: BLRK)
DMII vs BLRK Comparison August 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 645.9M. In comparison, BLRK has a market cap of 231.4M. Regarding current trading prices, DMII is priced at $10.14 on the NASDAQ, while BLRK trades at $10.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.43, whereas BLRK's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to BLRK's ROE of N/A. Regarding short-term risk, DMII is less volatile compared to BLRK. This indicates lower risk in terms of short-term price fluctuations for DMII.Check BLRK's competition here
Metals Acquisition Corp (NYSE: MTAL-WT)
DMII vs MTAL-WT Comparison August 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 645.9M. In comparison, MTAL-WT has a market cap of 230.4M. Regarding current trading prices, DMII is priced at $10.14 on the NASDAQ, while MTAL-WT trades at $1.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.43, whereas MTAL-WT's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to MTAL-WT's ROE of N/A. Regarding short-term risk, DMII is less volatile compared to MTAL-WT. This indicates lower risk in terms of short-term price fluctuations for DMII.Check MTAL-WT's competition here
Viking Acquisition Corp. II (NYSE: VII)
DMII vs VII Comparison August 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 645.9M. In comparison, VII has a market cap of 229.1M. Regarding current trading prices, DMII is priced at $10.14 on the NASDAQ, while VII trades at $9.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.43, whereas VII's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to VII's ROE of +0.00%. Regarding short-term risk, DMII is similarly volatile compared to VII. This indicates similar risk in terms of short-term price fluctuations for DMII.Check VII's competition here
Yorkville International Capital Corp. (NASDAQ: YICC)
DMII vs YICC Comparison August 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 645.9M. In comparison, YICC has a market cap of 228.2M. Regarding current trading prices, DMII is priced at $10.14 on the NASDAQ, while YICC trades at $9.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.43, whereas YICC's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to YICC's ROE of N/A. Regarding short-term risk, DMII is similarly volatile compared to YICC. This indicates similar risk in terms of short-term price fluctuations for DMII.Check YICC's competition here
Enhanced Group Inc. Class A (NYSE: ENHA)
DMII vs ENHA Comparison August 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 645.9M. In comparison, ENHA has a market cap of 222.6M. Regarding current trading prices, DMII is priced at $10.14 on the NASDAQ, while ENHA trades at $1.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.43, whereas ENHA's P/E ratio is -6.41. In terms of profitability, DMII's ROE is +0.03%, compared to ENHA's ROE of -0.86%. Regarding short-term risk, DMII is less volatile compared to ENHA. This indicates lower risk in terms of short-term price fluctuations for DMII.Check ENHA's competition here
Roman DBDR Acquisition Corp. II (NASDAQ: DRDBW)
DMII vs DRDBW Comparison August 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 645.9M. In comparison, DRDBW has a market cap of 219.6M. Regarding current trading prices, DMII is priced at $10.14 on the NASDAQ, while DRDBW trades at $0.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.43, whereas DRDBW's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to DRDBW's ROE of +0.02%. Regarding short-term risk, DMII is less volatile compared to DRDBW. This indicates lower risk in terms of short-term price fluctuations for DMII.Check DRDBW's competition here
Hall Chadwick Acquisition Corp. (NASDAQ: HCAC)
DMII vs HCAC Comparison August 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 645.9M. In comparison, HCAC has a market cap of 214.8M. Regarding current trading prices, DMII is priced at $10.14 on the NASDAQ, while HCAC trades at $10.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.43, whereas HCAC's P/E ratio is 369.23. In terms of profitability, DMII's ROE is +0.03%, compared to HCAC's ROE of -0.68%. Regarding short-term risk, DMII is less volatile compared to HCAC. This indicates lower risk in terms of short-term price fluctuations for DMII.Check HCAC's competition here
NewHold Investment Corp IV (NASDAQ: NHIVU)
DMII vs NHIVU Comparison August 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 645.9M. In comparison, NHIVU has a market cap of 212.9M. Regarding current trading prices, DMII is priced at $10.14 on the NASDAQ, while NHIVU trades at $10.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.43, whereas NHIVU's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to NHIVU's ROE of N/A. Regarding short-term risk, DMII is less volatile compared to NHIVU. This indicates lower risk in terms of short-term price fluctuations for DMII.Check NHIVU's competition here
RMG ML Sports Holdings (NASDAQ: SHOT)
DMII vs SHOT Comparison August 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 645.9M. In comparison, SHOT has a market cap of 212.8M. Regarding current trading prices, DMII is priced at $10.14 on the NASDAQ, while SHOT trades at $9.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.43, whereas SHOT's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to SHOT's ROE of +0.00%. Regarding short-term risk, DMII is less volatile compared to SHOT. This indicates lower risk in terms of short-term price fluctuations for DMII.Check SHOT's competition here
Social Commerce Partners Corporation (NASDAQ: SCPQW)
DMII vs SCPQW Comparison August 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 645.9M. In comparison, SCPQW has a market cap of 212.8M. Regarding current trading prices, DMII is priced at $10.14 on the NASDAQ, while SCPQW trades at $0.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.43, whereas SCPQW's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to SCPQW's ROE of N/A. Regarding short-term risk, DMII is less volatile compared to SCPQW. This indicates lower risk in terms of short-term price fluctuations for DMII.Check SCPQW's competition here
Safeguard Acquisition Corp. (NYSE: SAC-UN)
DMII vs SAC-UN Comparison August 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 645.9M. In comparison, SAC-UN has a market cap of 208M. Regarding current trading prices, DMII is priced at $10.14 on the NASDAQ, while SAC-UN trades at $10.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.43, whereas SAC-UN's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to SAC-UN's ROE of +0.00%. Regarding short-term risk, DMII is similarly volatile compared to SAC-UN. This indicates similar risk in terms of short-term price fluctuations for DMII.Check SAC-UN's competition here
TRG Latin America Acquisitions Corp. Class A Ordinary Shares (NASDAQ: TRGS)
DMII vs TRGS Comparison August 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 645.9M. In comparison, TRGS has a market cap of 207.1M. Regarding current trading prices, DMII is priced at $10.14 on the NASDAQ, while TRGS trades at $9.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.43, whereas TRGS's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to TRGS's ROE of N/A. Regarding short-term risk, DMII is similarly volatile compared to TRGS. This indicates similar risk in terms of short-term price fluctuations for DMII.Check TRGS's competition here
Vendome Acquisition Corporation I (NASDAQ: VNME)
DMII vs VNME Comparison August 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 645.9M. In comparison, VNME has a market cap of 205.4M. Regarding current trading prices, DMII is priced at $10.14 on the NASDAQ, while VNME trades at $10.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.43, whereas VNME's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to VNME's ROE of +18.81%. Regarding short-term risk, DMII is less volatile compared to VNME. This indicates lower risk in terms of short-term price fluctuations for DMII.Check VNME's competition here
Vendome Acquisition Corporation I Unit (NASDAQ: VNMEU)
DMII vs VNMEU Comparison August 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 645.9M. In comparison, VNMEU has a market cap of 205M. Regarding current trading prices, DMII is priced at $10.14 on the NASDAQ, while VNMEU trades at $10.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.43, whereas VNMEU's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to VNMEU's ROE of +18.81%. Regarding short-term risk, DMII is similarly volatile compared to VNMEU. This indicates similar risk in terms of short-term price fluctuations for DMII.Check VNMEU's competition here
Interprivate Investment Partners V Inc. (NASDAQ: IPVV)
DMII vs IPVV Comparison August 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 645.9M. In comparison, IPVV has a market cap of 202.9M. Regarding current trading prices, DMII is priced at $10.14 on the NASDAQ, while IPVV trades at $9.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.43, whereas IPVV's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to IPVV's ROE of N/A. Regarding short-term risk, DMII is less volatile compared to IPVV. This indicates lower risk in terms of short-term price fluctuations for DMII.Check IPVV's competition here
QDRO Acquisition Corp. Class A Ordinary Shares (NASDAQ: QADR)
DMII vs QADR Comparison August 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 645.9M. In comparison, QADR has a market cap of 199.6M. Regarding current trading prices, DMII is priced at $10.14 on the NASDAQ, while QADR trades at $9.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.43, whereas QADR's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to QADR's ROE of N/A. Regarding short-term risk, DMII is similarly volatile compared to QADR. This indicates similar risk in terms of short-term price fluctuations for DMII.Check QADR's competition here
QDRO Acquisition Corp. Units (NASDAQ: QADRU)
DMII vs QADRU Comparison August 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 645.9M. In comparison, QADRU has a market cap of 199.6M. Regarding current trading prices, DMII is priced at $10.14 on the NASDAQ, while QADRU trades at $10.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.43, whereas QADRU's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to QADRU's ROE of N/A. Regarding short-term risk, DMII is similarly volatile compared to QADRU. This indicates similar risk in terms of short-term price fluctuations for DMII.Check QADRU's competition here
Oceanhawk Acquisition Corp. Class A Ordinary Shares (NASDAQ: OHAC)
DMII vs OHAC Comparison August 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 645.9M. In comparison, OHAC has a market cap of 188.2M. Regarding current trading prices, DMII is priced at $10.14 on the NASDAQ, while OHAC trades at $9.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.43, whereas OHAC's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to OHAC's ROE of N/A. Regarding short-term risk, DMII is less volatile compared to OHAC. This indicates lower risk in terms of short-term price fluctuations for DMII.Check OHAC's competition here
Vendome Acquisition Corporation I Warrant (NASDAQ: VNMEW)
DMII vs VNMEW Comparison August 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 645.9M. In comparison, VNMEW has a market cap of 186.9M. Regarding current trading prices, DMII is priced at $10.14 on the NASDAQ, while VNMEW trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.43, whereas VNMEW's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to VNMEW's ROE of +18.81%. Regarding short-term risk, DMII is less volatile compared to VNMEW. This indicates lower risk in terms of short-term price fluctuations for DMII.Check VNMEW's competition here
Dynamix Corp (NASDAQ: ETHM)
DMII vs ETHM Comparison August 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 645.9M. In comparison, ETHM has a market cap of 180.6M. Regarding current trading prices, DMII is priced at $10.14 on the NASDAQ, while ETHM trades at $10.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.43, whereas ETHM's P/E ratio is -13.60. In terms of profitability, DMII's ROE is +0.03%, compared to ETHM's ROE of +0.62%. Regarding short-term risk, DMII is less volatile compared to ETHM. This indicates lower risk in terms of short-term price fluctuations for DMII.Check ETHM's competition here
Oceanhawk Acquisition Corp. Rights (NASDAQ: OHACR)
DMII vs OHACR Comparison August 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 645.9M. In comparison, OHACR has a market cap of 179.2M. Regarding current trading prices, DMII is priced at $10.14 on the NASDAQ, while OHACR trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.43, whereas OHACR's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to OHACR's ROE of N/A. Regarding short-term risk, DMII is less volatile compared to OHACR. This indicates lower risk in terms of short-term price fluctuations for DMII.Check OHACR's competition here
Jab Acquisition Corp. I (NASDAQ: JAB)
DMII vs JAB Comparison August 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 645.9M. In comparison, JAB has a market cap of 174M. Regarding current trading prices, DMII is priced at $10.14 on the NASDAQ, while JAB trades at $9.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.43, whereas JAB's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to JAB's ROE of N/A. Regarding short-term risk, DMII is less volatile compared to JAB. This indicates lower risk in terms of short-term price fluctuations for DMII.Check JAB's competition here
Long Table Growth Corp. Units (NASDAQ: LTGRU)
DMII vs LTGRU Comparison August 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 645.9M. In comparison, LTGRU has a market cap of 172.8M. Regarding current trading prices, DMII is priced at $10.14 on the NASDAQ, while LTGRU trades at $10.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.43, whereas LTGRU's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to LTGRU's ROE of N/A. Regarding short-term risk, DMII is less volatile compared to LTGRU. This indicates lower risk in terms of short-term price fluctuations for DMII.Check LTGRU's competition here
Long Table Growth Corp. (NASDAQ: LTGR)
DMII vs LTGR Comparison August 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 645.9M. In comparison, LTGR has a market cap of 172.2M. Regarding current trading prices, DMII is priced at $10.14 on the NASDAQ, while LTGR trades at $9.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.43, whereas LTGR's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to LTGR's ROE of N/A. Regarding short-term risk, DMII is less volatile compared to LTGR. This indicates lower risk in terms of short-term price fluctuations for DMII.Check LTGR's competition here
Paloma Acquisition Corp I Class A Ordinary Shares (NASDAQ: PALO)
DMII vs PALO Comparison August 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 645.9M. In comparison, PALO has a market cap of 169.5M. Regarding current trading prices, DMII is priced at $10.14 on the NASDAQ, while PALO trades at $9.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.43, whereas PALO's P/E ratio is -3220.97. In terms of profitability, DMII's ROE is +0.03%, compared to PALO's ROE of +0.00%. Regarding short-term risk, DMII is similarly volatile compared to PALO. This indicates similar risk in terms of short-term price fluctuations for DMII.Check PALO's competition here
Graf Global Corp. (AMEX: TONT)
DMII vs TONT Comparison August 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 645.9M. In comparison, TONT has a market cap of 153.6M. Regarding current trading prices, DMII is priced at $10.14 on the NASDAQ, while TONT trades at $10.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.43, whereas TONT's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to TONT's ROE of N/A. Regarding short-term risk, DMII is less volatile compared to TONT. This indicates lower risk in terms of short-term price fluctuations for DMII.Check TONT's competition here
Black Spade Acquisition II Co (NASDAQ: BSIIU)
DMII vs BSIIU Comparison August 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 645.9M. In comparison, BSIIU has a market cap of 152.8M. Regarding current trading prices, DMII is priced at $10.14 on the NASDAQ, while BSIIU trades at $9.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.43, whereas BSIIU's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to BSIIU's ROE of -266.79%. Regarding short-term risk, DMII is similarly volatile compared to BSIIU. This indicates similar risk in terms of short-term price fluctuations for DMII.Check BSIIU's competition here
Collective Acquisition Corp. (NASDAQ: CCAQ)
DMII vs CCAQ Comparison August 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 645.9M. In comparison, CCAQ has a market cap of 152.8M. Regarding current trading prices, DMII is priced at $10.14 on the NASDAQ, while CCAQ trades at $10.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.43, whereas CCAQ's P/E ratio is 40.58. In terms of profitability, DMII's ROE is +0.03%, compared to CCAQ's ROE of +0.03%. Regarding short-term risk, DMII is similarly volatile compared to CCAQ. This indicates similar risk in terms of short-term price fluctuations for DMII.Check CCAQ's competition here
Southern Cross Acquisition I Corp. (NASDAQ: NCO)
DMII vs NCO Comparison August 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 645.9M. In comparison, NCO has a market cap of 145.4M. Regarding current trading prices, DMII is priced at $10.14 on the NASDAQ, while NCO trades at $9.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.43, whereas NCO's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to NCO's ROE of N/A. Regarding short-term risk, DMII is less volatile compared to NCO. This indicates lower risk in terms of short-term price fluctuations for DMII.Check NCO's competition here
Breeze Acquisition Corp. II (NASDAQ: BREZ)
DMII vs BREZ Comparison August 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 645.9M. In comparison, BREZ has a market cap of 144.3M. Regarding current trading prices, DMII is priced at $10.14 on the NASDAQ, while BREZ trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.43, whereas BREZ's P/E ratio is -999.00. In terms of profitability, DMII's ROE is +0.03%, compared to BREZ's ROE of +0.53%. Regarding short-term risk, DMII is similarly volatile compared to BREZ. This indicates similar risk in terms of short-term price fluctuations for DMII.Check BREZ's competition here
Forefront Tech Holdings Acquisition Corp Unit (NASDAQ: FTHAU)
DMII vs FTHAU Comparison August 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 645.9M. In comparison, FTHAU has a market cap of 138.5M. Regarding current trading prices, DMII is priced at $10.14 on the NASDAQ, while FTHAU trades at $10.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.43, whereas FTHAU's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to FTHAU's ROE of N/A. Regarding short-term risk, DMII is less volatile compared to FTHAU. This indicates lower risk in terms of short-term price fluctuations for DMII.Check FTHAU's competition here
Collective Acquisition Corp. (NASDAQ: CCAQW)
DMII vs CCAQW Comparison August 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 645.9M. In comparison, CCAQW has a market cap of 135.8M. Regarding current trading prices, DMII is priced at $10.14 on the NASDAQ, while CCAQW trades at $0.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.43, whereas CCAQW's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to CCAQW's ROE of +0.03%. Regarding short-term risk, DMII is less volatile compared to CCAQW. This indicates lower risk in terms of short-term price fluctuations for DMII.Check CCAQW's competition here
Ocean Capital Acquisition Corporation (NYSE: OCAC)
DMII vs OCAC Comparison August 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 645.9M. In comparison, OCAC has a market cap of 135.6M. Regarding current trading prices, DMII is priced at $10.14 on the NASDAQ, while OCAC trades at $9.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.43, whereas OCAC's P/E ratio is -687.90. In terms of profitability, DMII's ROE is +0.03%, compared to OCAC's ROE of N/A. Regarding short-term risk, DMII is less volatile compared to OCAC. This indicates lower risk in terms of short-term price fluctuations for DMII.Check OCAC's competition here
East West Ave Acquisition Corp. Common Stock (NASDAQ: EWAV)
DMII vs EWAV Comparison August 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 645.9M. In comparison, EWAV has a market cap of 130.2M. Regarding current trading prices, DMII is priced at $10.14 on the NASDAQ, while EWAV trades at $9.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.43, whereas EWAV's P/E ratio is -14071.43. In terms of profitability, DMII's ROE is +0.03%, compared to EWAV's ROE of N/A. Regarding short-term risk, DMII is less volatile compared to EWAV. This indicates lower risk in terms of short-term price fluctuations for DMII.Check EWAV's competition here
Southern Cross Acquisition I Corp. (NASDAQ: NCOOU)
DMII vs NCOOU Comparison August 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 645.9M. In comparison, NCOOU has a market cap of 129M. Regarding current trading prices, DMII is priced at $10.14 on the NASDAQ, while NCOOU trades at $10.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.43, whereas NCOOU's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to NCOOU's ROE of N/A. Regarding short-term risk, DMII is less volatile compared to NCOOU. This indicates lower risk in terms of short-term price fluctuations for DMII.Check NCOOU's competition here
Breeze Acquisition Corp. II (NASDAQ: BREZR)
DMII vs BREZR Comparison August 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 645.9M. In comparison, BREZR has a market cap of 122.6M. Regarding current trading prices, DMII is priced at $10.14 on the NASDAQ, while BREZR trades at $0.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.43, whereas BREZR's P/E ratio is -23.00. In terms of profitability, DMII's ROE is +0.03%, compared to BREZR's ROE of +0.53%. Regarding short-term risk, DMII is less volatile compared to BREZR. This indicates lower risk in terms of short-term price fluctuations for DMII.Check BREZR's competition here
Shepherd Ave Capital Acquisition Corporation (NASDAQ: SPHA)
DMII vs SPHA Comparison August 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 645.9M. In comparison, SPHA has a market cap of 111.7M. Regarding current trading prices, DMII is priced at $10.14 on the NASDAQ, while SPHA trades at $10.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.43, whereas SPHA's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to SPHA's ROE of -1.30%. Regarding short-term risk, DMII is less volatile compared to SPHA. This indicates lower risk in terms of short-term price fluctuations for DMII.Check SPHA's competition here
Amanat Acquisition Corp Class A Ordinary Shares (NASDAQ: AMAN)
DMII vs AMAN Comparison August 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 645.9M. In comparison, AMAN has a market cap of 103.4M. Regarding current trading prices, DMII is priced at $10.14 on the NASDAQ, while AMAN trades at $10.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.43, whereas AMAN's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to AMAN's ROE of N/A. Regarding short-term risk, DMII is less volatile compared to AMAN. This indicates lower risk in terms of short-term price fluctuations for DMII.Check AMAN's competition here
Research Alliance Corp. Iv (NASDAQ: RACD)
DMII vs RACD Comparison August 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 645.9M. In comparison, RACD has a market cap of 96.9M. Regarding current trading prices, DMII is priced at $10.14 on the NASDAQ, while RACD trades at $12.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.43, whereas RACD's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to RACD's ROE of N/A. Regarding short-term risk, DMII is less volatile compared to RACD. This indicates lower risk in terms of short-term price fluctuations for DMII.Check RACD's competition here
Cayson Acquisition Corp (NASDAQ: CAPNU)
DMII vs CAPNU Comparison August 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 645.9M. In comparison, CAPNU has a market cap of 94M. Regarding current trading prices, DMII is priced at $10.14 on the NASDAQ, while CAPNU trades at $11.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.43, whereas CAPNU's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to CAPNU's ROE of +0.03%. Regarding short-term risk, DMII is similarly volatile compared to CAPNU. This indicates similar risk in terms of short-term price fluctuations for DMII.Check CAPNU's competition here
Miluna Acquisition Corp Class A Ordinary Share (NASDAQ: MMTX)
DMII vs MMTX Comparison August 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 645.9M. In comparison, MMTX has a market cap of 89.7M. Regarding current trading prices, DMII is priced at $10.14 on the NASDAQ, while MMTX trades at $10.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.43, whereas MMTX's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to MMTX's ROE of +0.02%. Regarding short-term risk, DMII is less volatile compared to MMTX. This indicates lower risk in terms of short-term price fluctuations for DMII.Check MMTX's competition here
Peace Acquisition Corp Units (NASDAQ: PECEU)
DMII vs PECEU Comparison August 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 645.9M. In comparison, PECEU has a market cap of 86.8M. Regarding current trading prices, DMII is priced at $10.14 on the NASDAQ, while PECEU trades at $10.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.43, whereas PECEU's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to PECEU's ROE of N/A. Regarding short-term risk, DMII is similarly volatile compared to PECEU. This indicates similar risk in terms of short-term price fluctuations for DMII.Check PECEU's competition here
YHN Acquisition I Limited Unit (NASDAQ: YHNAU)
DMII vs YHNAU Comparison August 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 645.9M. In comparison, YHNAU has a market cap of 86.2M. Regarding current trading prices, DMII is priced at $10.14 on the NASDAQ, while YHNAU trades at $11.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.43, whereas YHNAU's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to YHNAU's ROE of +0.09%. Regarding short-term risk, DMII is similarly volatile compared to YHNAU. This indicates similar risk in terms of short-term price fluctuations for DMII.Check YHNAU's competition here
Calisa Acquisition Corp (NASDAQ: ALIS)
DMII vs ALIS Comparison August 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 645.9M. In comparison, ALIS has a market cap of 86M. Regarding current trading prices, DMII is priced at $10.14 on the NASDAQ, while ALIS trades at $10.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.43, whereas ALIS's P/E ratio is 510.50. In terms of profitability, DMII's ROE is +0.03%, compared to ALIS's ROE of +0.01%. Regarding short-term risk, DMII is less volatile compared to ALIS. This indicates lower risk in terms of short-term price fluctuations for DMII.Check ALIS's competition here
FTAC Emerald Acquisition Corp. (NASDAQ: FLDD)
DMII vs FLDD Comparison August 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 645.9M. In comparison, FLDD has a market cap of 85.6M. Regarding current trading prices, DMII is priced at $10.14 on the NASDAQ, while FLDD trades at $6.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.43, whereas FLDD's P/E ratio is -75.13. In terms of profitability, DMII's ROE is +0.03%, compared to FLDD's ROE of N/A. Regarding short-term risk, DMII is less volatile compared to FLDD. This indicates lower risk in terms of short-term price fluctuations for DMII.Check FLDD's competition here
Horizon Quantum Holdings Ltd. Warrant (NASDAQ: HQWWW)
DMII vs HQWWW Comparison August 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 645.9M. In comparison, HQWWW has a market cap of 81.9M. Regarding current trading prices, DMII is priced at $10.14 on the NASDAQ, while HQWWW trades at $10.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.43, whereas HQWWW's P/E ratio is -46.73. In terms of profitability, DMII's ROE is +0.03%, compared to HQWWW's ROE of -2.86%. Regarding short-term risk, DMII is less volatile compared to HQWWW. This indicates lower risk in terms of short-term price fluctuations for DMII.Check HQWWW's competition here
Twenty One Capital Inc (NYSE: XXI)
DMII vs XXI Comparison August 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 645.9M. In comparison, XXI has a market cap of 66.7M. Regarding current trading prices, DMII is priced at $10.14 on the NASDAQ, while XXI trades at $6.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.43, whereas XXI's P/E ratio is -46.29. In terms of profitability, DMII's ROE is +0.03%, compared to XXI's ROE of -0.72%. Regarding short-term risk, DMII is less volatile compared to XXI. This indicates lower risk in terms of short-term price fluctuations for DMII.Check XXI's competition here
Bayview Acquisition Corp Unit (NASDAQ: BAYAU)
DMII vs BAYAU Comparison August 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 645.9M. In comparison, BAYAU has a market cap of 63.1M. Regarding current trading prices, DMII is priced at $10.14 on the NASDAQ, while BAYAU trades at $12.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.43, whereas BAYAU's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to BAYAU's ROE of -0.03%. Regarding short-term risk, DMII is less volatile compared to BAYAU. This indicates lower risk in terms of short-term price fluctuations for DMII.Check BAYAU's competition here
Westin Acquisition Corp (NASDAQ: WSTNR)
DMII vs WSTNR Comparison August 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 645.9M. In comparison, WSTNR has a market cap of 61.3M. Regarding current trading prices, DMII is priced at $10.14 on the NASDAQ, while WSTNR trades at $0.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.43, whereas WSTNR's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to WSTNR's ROE of +0.01%. Regarding short-term risk, DMII is less volatile compared to WSTNR. This indicates lower risk in terms of short-term price fluctuations for DMII.Check WSTNR's competition here
Blueport Acquisition Ltd (NASDAQ: BPACU)
DMII vs BPACU Comparison August 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 645.9M. In comparison, BPACU has a market cap of 61.3M. Regarding current trading prices, DMII is priced at $10.14 on the NASDAQ, while BPACU trades at $10.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.43, whereas BPACU's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to BPACU's ROE of +0.07%. Regarding short-term risk, DMII is similarly volatile compared to BPACU. This indicates similar risk in terms of short-term price fluctuations for DMII.Check BPACU's competition here
Blueport Acquisition Ltd (NASDAQ: BPAC)
DMII vs BPAC Comparison August 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 645.9M. In comparison, BPAC has a market cap of 60.6M. Regarding current trading prices, DMII is priced at $10.14 on the NASDAQ, while BPAC trades at $10.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.43, whereas BPAC's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to BPAC's ROE of +0.01%. Regarding short-term risk, DMII is less volatile compared to BPAC. This indicates lower risk in terms of short-term price fluctuations for DMII.Check BPAC's competition here
Cartesian Growth Corporation III (NASDAQ: CGCTW)
DMII vs CGCTW Comparison August 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 645.9M. In comparison, CGCTW has a market cap of 50.4M. Regarding current trading prices, DMII is priced at $10.14 on the NASDAQ, while CGCTW trades at $1.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.43, whereas CGCTW's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to CGCTW's ROE of -0.15%. Regarding short-term risk, DMII is less volatile compared to CGCTW. This indicates lower risk in terms of short-term price fluctuations for DMII.Check CGCTW's competition here
CoinShares PLC (NASDAQ: CSHRW)
DMII vs CSHRW Comparison August 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 645.9M. In comparison, CSHRW has a market cap of 48.1M. Regarding current trading prices, DMII is priced at $10.14 on the NASDAQ, while CSHRW trades at $0.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.43, whereas CSHRW's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to CSHRW's ROE of N/A. Regarding short-term risk, DMII is less volatile compared to CSHRW. This indicates lower risk in terms of short-term price fluctuations for DMII.Check CSHRW's competition here
YHN Acquisition I Limited (NASDAQ: YHNA)
DMII vs YHNA Comparison August 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 645.9M. In comparison, YHNA has a market cap of 47M. Regarding current trading prices, DMII is priced at $10.14 on the NASDAQ, while YHNA trades at $10.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.43, whereas YHNA's P/E ratio is 84.38. In terms of profitability, DMII's ROE is +0.03%, compared to YHNA's ROE of +0.09%. Regarding short-term risk, DMII is less volatile compared to YHNA. This indicates lower risk in terms of short-term price fluctuations for DMII.Check YHNA's competition here
Horizon Space Acquisition II Corp. (NASDAQ: HSPT)
DMII vs HSPT Comparison August 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 645.9M. In comparison, HSPT has a market cap of 46.4M. Regarding current trading prices, DMII is priced at $10.14 on the NASDAQ, while HSPT trades at $5.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.43, whereas HSPT's P/E ratio is 41.86. In terms of profitability, DMII's ROE is +0.03%, compared to HSPT's ROE of +0.04%. Regarding short-term risk, DMII is less volatile compared to HSPT. This indicates lower risk in terms of short-term price fluctuations for DMII.Check HSPT's competition here
Spring Valley Acquisition Corp. III (NASDAQ: SVACW)
DMII vs SVACW Comparison August 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 645.9M. In comparison, SVACW has a market cap of 43.2M. Regarding current trading prices, DMII is priced at $10.14 on the NASDAQ, while SVACW trades at $1.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.43, whereas SVACW's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to SVACW's ROE of -5.09%. Regarding short-term risk, DMII is less volatile compared to SVACW. This indicates lower risk in terms of short-term price fluctuations for DMII.Check SVACW's competition here
Sol Strategies Inc. Common Shares (NASDAQ: STKE)
DMII vs STKE Comparison August 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 645.9M. In comparison, STKE has a market cap of 33.9M. Regarding current trading prices, DMII is priced at $10.14 on the NASDAQ, while STKE trades at $1.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.43, whereas STKE's P/E ratio is -0.41. In terms of profitability, DMII's ROE is +0.03%, compared to STKE's ROE of -262023.91%. Regarding short-term risk, DMII is less volatile compared to STKE. This indicates lower risk in terms of short-term price fluctuations for DMII.Check STKE's competition here
Columbus Circle Capital Corp II (NASDAQ: CMIIW)
DMII vs CMIIW Comparison August 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 645.9M. In comparison, CMIIW has a market cap of 30.8M. Regarding current trading prices, DMII is priced at $10.14 on the NASDAQ, while CMIIW trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.43, whereas CMIIW's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to CMIIW's ROE of N/A. Regarding short-term risk, DMII is less volatile compared to CMIIW. This indicates lower risk in terms of short-term price fluctuations for DMII.Check CMIIW's competition here
Mountain Lake Acquisition Corp. Class A (NASDAQ: MLAC)
DMII vs MLAC Comparison August 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 645.9M. In comparison, MLAC has a market cap of 30.4M. Regarding current trading prices, DMII is priced at $10.14 on the NASDAQ, while MLAC trades at $0.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.43, whereas MLAC's P/E ratio is 3.77. In terms of profitability, DMII's ROE is +0.03%, compared to MLAC's ROE of +0.03%. Regarding short-term risk, DMII is less volatile compared to MLAC. This indicates lower risk in terms of short-term price fluctuations for DMII.Check MLAC's competition here
East West Ave Acquisition Corp. (NASDAQ: EWAVU)
DMII vs EWAVU Comparison August 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 645.9M. In comparison, EWAVU has a market cap of 26.1M. Regarding current trading prices, DMII is priced at $10.14 on the NASDAQ, while EWAVU trades at $9.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.43, whereas EWAVU's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to EWAVU's ROE of N/A. Regarding short-term risk, DMII is similarly volatile compared to EWAVU. This indicates similar risk in terms of short-term price fluctuations for DMII.Check EWAVU's competition here
Space Asset Acquisition Corp. Warrants (NASDAQ: SAAQW)
DMII vs SAAQW Comparison August 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 645.9M. In comparison, SAAQW has a market cap of 18.6M. Regarding current trading prices, DMII is priced at $10.14 on the NASDAQ, while SAAQW trades at $0.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.43, whereas SAAQW's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to SAAQW's ROE of N/A. Regarding short-term risk, DMII is less volatile compared to SAAQW. This indicates lower risk in terms of short-term price fluctuations for DMII.Check SAAQW's competition here